CAR-T Membrane Coated Nanoparticles for Targeted Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nanoparticle-based drug delivery systems face challenges such as inefficient targeting, immune system uptake, and adverse effects due to high ligand density on the surface, leading to non-specific binding and reduced efficacy in delivering therapeutic agents to cancer cells.
Innovation Solution
Development of chimeric antigen receptor (CAR) engineered T lymphocyte membrane coated nanoparticles (CAR-T MNPs) that utilize a bi-specific CAR with intracellular and extracellular binding moieties and are coated with a therapeutic agent, specifically designed to target cancer cells using PLGA as the engineered particle, enhancing targeted delivery and reducing systemic toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If targeting ligands are conjugated on synthetic drug carrier nanoparticle surfaces to enable active targeting, then targeting efficiency is improved, but ligands are prone to shed off during degradation and density is reduced leading to ineffective targeting
Solution Approach 1:
The patent uses a hybrid nanoparticle system combining synthetic PLGA core with natural T-cell membrane coating. The membrane contains native targeting ligands that are not conjugated but naturally present, eliminating the shedding problem while maintaining targeting function. This composite structure merges the controlled release advantage of synthetic carriers with the stability and targeting capability of biological membranes.
Solution Approach 2:
The patent changes the state of targeting ligands from conjugated (on synthetic carriers) to native (on cell membranes). This parameter change transforms the ligands from vulnerable conjugated molecules to stable integral membrane components, resolving the shedding issue while preserving targeting efficiency.
2Reliability
If high ligand density is used on nanoparticle surface to improve targeting, then targeting efficiency increases, but non-specific binding and immune system uptake increase leading to adverse effects
Solution Approach 1:
The T-cell membrane coating provides localized distribution of targeting ligands at specific regions of the nanoparticle surface. This natural distribution pattern avoids the uniform high-density conjugation that causes non-specific binding, while maintaining effective targeting at the intended site.
Solution Approach 2:
The patent changes the density parameter from high conjugated ligand density to physiological ligand density on membrane surface. This natural density reduces non-specific interactions and immune recognition while maintaining sufficient targeting capability through the native ligand-receptor interactions.
3Reliability
If conventional chemotherapy is used to treat lung cancer, then cancer cells can be treated, but systemic organ toxicity occurs including hair loss, nausea, fatigue, and nerve damage
Solution Approach 1:
The patent segments the therapeutic approach by delivering chemotherapy drugs locally to tumor sites through targeted nanoparticles rather than systemic administration. This segmentation concentrates the therapeutic effect at the tumor while minimizing exposure of healthy organs to toxic drugs, reducing side effects like hair loss, nausea, and nerve damage.
Solution Approach 2:
The T-cell membrane coated nanoparticles serve as an intermediary vehicle that carries chemotherapy drugs to tumor cells. This intermediary enables selective drug delivery to cancer cells expressing specific antigens, preventing direct contact between systemic chemotherapy and healthy tissues, thereby reducing toxicity.
4Reliability
If surgical removal of tumors is performed, then cancer can be treated, but it is not feasible for 30-40% of patients with unresectable tumors
Solution Approach 1:
The patent creates a universal treatment platform that can be applied to both resectable and unresectable tumors. The targeted nanoparticle system works regardless of tumor location or accessibility, making it applicable to the 30-40% of patients for whom surgery is not an option, while also serving as an alternative for resectable cases.
Data Source
AI summary
Disclosed are chimeric antigen receptor (CAR) engineered T lymphocyte membrane coated nanoparticles (CAR-T MNP) compositions and methods of using the same for delivering therapeutics to a particular target.